Literature DB >> 25662428

ATP1A3 mutation in a Chinese girl with alternating hemiplegia of childhood--Potential target of treatment?

Virginia C N Wong1, Anna K Y Kwong2.   

Abstract

BACKGROUND: This Chinese girl had alternating hemiplegia of childhood (AHC) since 2 months. She failed to respond to anticonvulsants, antimigrainous drugs and calcium channel blockers but achieved complete remission steroid treatment for 4 weeks and relapsed after stopping steroid.
PURPOSE: In order to clarify the unknown etiology, genetic analysis of ATP1A3 gene, which encodes the alpha3-subunit of the sodium/potassium-transporting ATPase (Na, K-ATPase), has been done by Sanger sequencing.
RESULTS: A de novo heterozygous missense mutation (c.2401G>A; p.D801N) was identified in exon 17 of ATP1A3 gene and this is one of the hotspot mutations found in AHC patients.
CONCLUSION: It will be interesting to further investigate whether Na, K-ATPase was the target of corticosteroid treatment.
Copyright © 2015 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ATP1A3; Alternating hemiplegia; Corticosteroid; Na, K-ATPase; Sodium/potassium-transporting ATPase

Mesh:

Substances:

Year:  2015        PMID: 25662428     DOI: 10.1016/j.braindev.2015.01.003

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  2 in total

Review 1.  Diagnosis and Treatment of Alternating Hemiplegia of Childhood.

Authors:  Melanie Masoud; Lyndsey Prange; Jeffrey Wuchich; Arsen Hunanyan; Mohamad A Mikati
Journal:  Curr Treat Options Neurol       Date:  2017-02       Impact factor: 3.598

Review 2.  The Influence of Na(+), K(+)-ATPase on Glutamate Signaling in Neurodegenerative Diseases and Senescence.

Authors:  Paula F Kinoshita; Jacqueline A Leite; Ana Maria M Orellana; Andrea R Vasconcelos; Luis E M Quintas; Elisa M Kawamoto; Cristoforo Scavone
Journal:  Front Physiol       Date:  2016-06-02       Impact factor: 4.566

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.